Business   

Indoco to sell ophthalmic products in the U.S.

CHENNAI: Driven by demographic trends, such as an increasing aged population, the global ophthalmic pharmaceutical market is set to witness an aggressive growth. The market is currently valued at $9.25 billion and revenues are forecast to rise to over $14 billion by the end of 2009.

In an interaction with The Hindu, Aditi Kare Panandikar, Director, Business Development, Indoco Remedies, said glaucoma therapies were set to dominate the market accounting for almost 40 per cent of revenues by 2009.

Indeed, 2004 saw the first blockbuster prostaglandin ophthalmic drug, Xalatan, used to treat glaucoma.

“We have identified prostaglandin products as potential items for the U.S markets and have a few of these in the pipeline,” she said.

Indoco Remedies is engaged in the manufacture of a wide range of products in various therapeutic segments. “Indoco’s strength with USFDA approved eye drops facility at Goa, strong R&D capability to formulate difficult to develop products and its own backward integration with API source make a definite advantage,” Ms. Aditi said. The company has recently entered into a joint-venture with Amneal pharmaceuticals, a New Jersey-based generic pharma company, to market its ophthalmic range of products in the U.S. As part of the agreement, ANDAs (abbreviated new drug applications) of ten ophthalmic products were selected for this year.

Printer friendly page  
Send this article to Friends by E-Mail

Stories in this Section

State Bank clocks higher profit in first quarter
Treasury income pulls down ICICI Bank net profit in Q1
‘India Expo’ in Singapore next month
Indoco to sell ophthalmic products in the U.S.
Exim Bank expands Indian infra facility with ICICI Bank
Suncity to develop retail malls
New Kappa engine for Hyundai’s i10
Maruti posts 12 per cent growth
DATA (Kerala) office-bearers
CSI office-bearers
Geojit clears 70% dividend
Bullion Rates

Copyright © 2008, The Hindu. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu